Cadrenal Therapeutics Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, Cadrenal Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $27.67. The average 1-year stock price forecast is 435.20% higher than the current stock price, while the lowest is $13 (+151.45%) and the highest is $45 (+770.41%).

Price Target: $27.67 (+435.20%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$13	$27.67	$25	$45
Change	+151.45%	+435.20%	+383.56%	+770.41%

* Price targets were last updated on Apr 7, 2026.

Analyst Ratings

The average analyst rating for Cadrenal Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	1	1	1	1	1	1
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Joseph Pantginis HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $32 → $13	Strong Buy	Maintains	$32 → $13	+151.45%	Apr 7, 2026
Joseph Pantginis HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $32	Strong Buy	Reiterates	$32	+518.96%	May 16, 2025
Joseph Pantginis HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $3 → $32	Strong Buy	Maintains	$3 → $32	+518.96%	Nov 11, 2024
Joseph Pantginis HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $45	Strong Buy	Reiterates	$45	+770.41%	Jun 6, 2024
Joseph Pantginis HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $45	Strong Buy	Reiterates	$45	+770.41%	May 9, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-6.41

from -6.64

EPS Next Year

-2.99

from -6.41

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027	Dec 31, 2028
Revenue	-	-	-	-	-	-	-
Revenue Growth	-	-	-	-	-	-	-
EPS	-13.92	-9.29	-8.73	-6.64	-6.41	-2.99	-2.95
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	4	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	n/a
Avg	n/a	n/a
Low	n/a	n/a

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-5.06	-3.08
Avg	-6.41	-2.99
Low	-7.59	-2.87

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.